These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 24216320)

  • 1. Current status and future prospects of toxicogenomics in drug discovery.
    Khan SR; Baghdasarian A; Fahlman RP; Michail K; Siraki AG
    Drug Discov Today; 2014 May; 19(5):562-78. PubMed ID: 24216320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toxicogenomics in drug discovery: from preclinical studies to clinical trials.
    Yang Y; Blomme EA; Waring JF
    Chem Biol Interact; 2004 Nov; 150(1):71-85. PubMed ID: 15522262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Japanese toxicogenomics project: application of toxicogenomics.
    Uehara T; Ono A; Maruyama T; Kato I; Yamada H; Ohno Y; Urushidani T
    Mol Nutr Food Res; 2010 Feb; 54(2):218-27. PubMed ID: 20041446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Strategic applications of toxicogenomics in early drug discovery.
    Ryan TP; Stevens JL; Thomas CE
    Curr Opin Pharmacol; 2008 Oct; 8(5):654-60. PubMed ID: 18760379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Current and future views from pharmaceutical industry perspectives on development of antidepressants].
    Arano I; Imaeda T
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2011 Aug; 31(4):181-6. PubMed ID: 21941853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toxicogenomics in drug discovery and development -- making an impact.
    Wills Q; Mitchell C
    Altern Lab Anim; 2009 Sep; 37 Suppl 1():33-7. PubMed ID: 19807202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effective global drug development strategy for obtaining regulatory approval in Japan in the context of ethnicity-related drug response factors.
    Ichimaru K; Toyoshima S; Uyama Y
    Clin Pharmacol Ther; 2010 Mar; 87(3):362-6. PubMed ID: 20107436
    [No Abstract]   [Full Text] [Related]  

  • 8. Toxicogenomics of A375 human malignant melanoma cells.
    Cheng SL; Huang-Liu R; Sheu JN; Chen ST; Sinchaikul S; Tsay GJ
    Pharmacogenomics; 2007 Aug; 8(8):1017-36. PubMed ID: 17716235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibacterial drug development: challenges, recent developments, and future considerations.
    Nambiar S; Laessig K; Toerner J; Farley J; Cox E
    Clin Pharmacol Ther; 2014 Aug; 96(2):147-9. PubMed ID: 25056394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploiting pluripotent stem cell technology for drug discovery, screening, safety, and toxicology assessments.
    McGivern JV; Ebert AD
    Adv Drug Deliv Rev; 2014 Apr; 69-70():170-8. PubMed ID: 24309014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Looking forward in pharmaceutical process chemistry.
    Davies IW; Welch CJ
    Science; 2009 Aug; 325(5941):701-4. PubMed ID: 19661417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SimuGen Ltd: reliable, early prediction of drug toxicity with toxicogenomics, human cell culture and computational models.
    Wills Q
    Pharmacogenomics; 2007 Aug; 8(8):1081-4. PubMed ID: 17716240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The state-of-the-art in predictive toxicogenomics.
    Fielden MR; Kolaja KL
    Curr Opin Drug Discov Devel; 2006 Jan; 9(1):84-91. PubMed ID: 16445120
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current and future use of genomics data in toxicology: opportunities and challenges for regulatory applications.
    Goetz AK; Singh BP; Battalora M; Breier JM; Bailey JP; Chukwudebe AC; Janus ER
    Regul Toxicol Pharmacol; 2011 Nov; 61(2):141-53. PubMed ID: 21840362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toxicogenomics in predictive toxicology in drug development.
    Suter L; Babiss LE; Wheeldon EB
    Chem Biol; 2004 Feb; 11(2):161-71. PubMed ID: 15123278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New drugs and new regimens for the treatment of tuberculosis: review of the drug development pipeline and implications for national programmes.
    Lienhardt C; Vernon A; Raviglione MC
    Curr Opin Pulm Med; 2010 May; 16(3):186-93. PubMed ID: 20216421
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Toxicogenomics in drug discovery and drug development: potential applications and future challenges.
    Khor TO; Ibrahim S; Kong AN
    Pharm Res; 2006 Aug; 23(8):1659-64. PubMed ID: 16858654
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Iconix Biosciences, Inc.
    Fielden MR; Halbert DN
    Pharmacogenomics; 2007 Apr; 8(4):401-5. PubMed ID: 17391077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathway analysis tools and toxicogenomics reference databases for risk assessment.
    Ganter B; Zidek N; Hewitt PR; Müller D; Vladimirova A
    Pharmacogenomics; 2008 Jan; 9(1):35-54. PubMed ID: 18154447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Future of toxicogenomics and safety signatures: balancing public access to data with proprietary drug discovery.
    Fostel JM
    Pharmacogenomics; 2007 May; 8(5):425-30. PubMed ID: 17465705
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.